Business
INOVIO Announces Dosing of First Subject in Phase 1/2 Clinical Trial for INO-3107, its DNA Medicine to Treat a Rare Disease Recurrent Respiratory Papillomatosis (RRP)
PLYMOUTH MEETING, Pa., Nov. 23, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA
About this update from Inovio Pharmaceuticals, Inc.
[{"type":"text","content":"PLYMOUTH MEETING, Pa., Nov. 23, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced it has dosed its first subject with DNA medicine INO-3107 in a Phase 1/2 clinical trial for the treatment of Recurrent Respiratory Papillomatosis (RRP).\nRRP is a rare disease caused by the human papillomavirus (HPV) types 6 and 11 infections, a condition that causes non-cancerous tumor growths leading to life-threatening airway obstructions. The disease is currently incurable and is mostly treated by surgery, which temporarily restores the airway. The majority of tumors are recurring, necessitating repeated surgery and severely impacting the quality of life for those living with the disease. Earlier this year, the US Food and Drug Administration (FDA) granted INO-3107 Orphan Drug Designation.\nDr. J. Joseph Kim, President and CEO of INOVIO, said, \"We are extremely excited to be able to advance a potentially life-changing, innovative therapy like INO-3107 to patients with RRP, a devastating disease that significantly impacts quality of life. Our Phase 1/2 trial builds on our promising pipeline of HPV programs that also includes our Phase 3 REVEAL studies in HPV-16/HPV-18-related pre-cancerous cervical disease, as well as in HPV-16/HPV-18 vulvar and anal neoplasia. We are encouraged by the plethora of prior data from these programs, and the potential for INO-3107 to show clinical benefit to these patients who suffer from the life-long illness of RRP.\"\nDr. Ted Mau, Assistant Professor of Otolaryngology, Head and Neck Surgery, at UT Southwestern Medical Center, and lead investigator for INOVIO's RRP Phase 1/2 clinical trial, said, \"As a surgeon, I have had patients who have required dozens of surgeries and are looking at many more during their lifetimes. This new systemic therapy is specific for RRP and has the potential to meaningfully alter the treatment paradigm for patients living with this disease.\"\nAbout the INO-3107 Phase 1/2 Clinical Trial\nThe trial, called RRP-001, is a clinical trial investigating the efficacy and safety of INOVIO's novel HPV-6/HPV-11 therapy in subjects with RRP, designed to eradicate both the cause, and sequelae, of infection of the airway with HPV. The open...